181 related articles for article (PubMed ID: 12234611)
1. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476
[TBL] [Abstract][Full Text] [Related]
3. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
[TBL] [Abstract][Full Text] [Related]
4. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
Savickiene J; Treigyte G; Borutinskaite V; Navakauskiene R; Magnusson KE
Ann N Y Acad Sci; 2006 Dec; 1091():368-84. PubMed ID: 17341629
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
Kosugi H; Ito M; Yamamoto Y; Towatari M; Ito M; Ueda R; Saito H; Naoe T
Jpn J Cancer Res; 2001 May; 92(5):529-36. PubMed ID: 11376562
[TBL] [Abstract][Full Text] [Related]
8. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.
Sasakawa Y; Naoe Y; Sogo N; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2005 Feb; 69(4):603-16. PubMed ID: 15670579
[TBL] [Abstract][Full Text] [Related]
9. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.
Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Cancer Lett; 2003 Jun; 195(2):161-8. PubMed ID: 12767524
[TBL] [Abstract][Full Text] [Related]
10. Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228.
Fecteau KA; Mei J; Wang HC
J Pharmacol Exp Ther; 2002 Mar; 300(3):890-9. PubMed ID: 11861795
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
12. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
Karam JA; Fan J; Stanfield J; Richer E; Benaim EA; Frenkel E; Antich P; Sagalowsky AI; Mason RP; Hsieh JT
Int J Cancer; 2007 Apr; 120(8):1795-802. PubMed ID: 17230511
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells.
Murata M; Towatari M; Kosugi H; Tanimoto M; Ueda R; Saito H; Naoe T
Jpn J Cancer Res; 2000 Nov; 91(11):1154-60. PubMed ID: 11092981
[TBL] [Abstract][Full Text] [Related]
14. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.
Yu X; Guo ZS; Marcu MG; Neckers L; Nguyen DM; Chen GA; Schrump DS
J Natl Cancer Inst; 2002 Apr; 94(7):504-13. PubMed ID: 11929951
[TBL] [Abstract][Full Text] [Related]
15. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
Xiao JJ; Foraker AB; Swaan PW; Liu S; Huang Y; Dai Z; Chen J; Sadée W; Byrd J; Marcucci G; Chan KK
J Pharmacol Exp Ther; 2005 Apr; 313(1):268-76. PubMed ID: 15634944
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.
Sawa H; Murakami H; Kumagai M; Nakasato M; Yamauchi S; Matsuyama N; Tamura Y; Satone A; Ide W; Hashimoto I; Kamada H
Acta Neuropathol; 2004 Jun; 107(6):523-31. PubMed ID: 15024582
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Goldsmith ME; Aguila A; Steadman K; Martinez A; Steinberg SM; Alley MC; Waud WR; Bates SE; Fojo T
Mol Cancer Ther; 2007 Feb; 6(2):496-505. PubMed ID: 17308048
[TBL] [Abstract][Full Text] [Related]
18. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
Sato N; Ohta T; Kitagawa H; Kayahara M; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2004 Mar; 24(3):679-85. PubMed ID: 14767553
[TBL] [Abstract][Full Text] [Related]
19. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.
Sandor V; Senderowicz A; Mertins S; Sackett D; Sausville E; Blagosklonny MV; Bates SE
Br J Cancer; 2000 Sep; 83(6):817-25. PubMed ID: 10952788
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
